Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102

1.

Role of mir-15a/16-1 in early B cell development in a mouse model of chronic lymphocytic leukemia.

Underbayev C, Kasar S, Ruezinsky W, Degheidy H, Schneider JS, Marti G, Bauer SR, Fraidenraich D, Lightfoote MM, Parashar V, Raveche E, Batish M.

Oncotarget. 2016 Sep 20;7(38):60986-60999. doi: 10.18632/oncotarget.11290.

2.

Concerted action of IFN-α and IFN-λ induces local NK cell immunity and halts cancer growth.

Lasfar A, de laTorre A, Abushahba W, Cohen-Solal KA, Castaneda I, Yuan Y, Reuhl K, Zloza A, Raveche E, Laskin DL, Kotenko SV.

Oncotarget. 2016 Aug 2;7(31):49259-49267. doi: 10.18632/oncotarget.10272.

3.

Alterations in the mir-15a/16-1 Loci Impairs Its Processing and Augments B-1 Expansion in De Novo Mouse Model of Chronic Lymphocytic Leukemia (CLL).

Kasar S, Underbayev C, Hassan M, Ilev I, Degheidy H, Bauer S, Marti G, Lutz C, Raveche E, Batish M.

PLoS One. 2016 Mar 9;11(3):e0149331. doi: 10.1371/journal.pone.0149331. eCollection 2016.

4.

Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study.

Landgren O, Shim YK, Michalek J, Costello R, Burton D, Ketchum N, Calvo KR, Caporaso N, Raveche E, Middleton D, Marti G, Vogt RF Jr.

JAMA Oncol. 2015 Nov;1(8):1061-8. doi: 10.1001/jamaoncol.2015.2938.

5.

Reversible mitochondrial DNA accumulation in nuclei of pluripotent stem cells.

Schneider JS, Cheng X, Zhao Q, Underbayev C, Gonzalez JP, Raveche ES, Fraidenraich D, Ivessa AS.

Stem Cells Dev. 2014 Nov 15;23(22):2712-9. doi: 10.1089/scd.2013.0630. Epub 2014 Aug 4.

6.

Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a/16-1 in chronic lymphocytic leukemia.

Kasar S, Underbayev C, Yuan Y, Hanlon M, Aly S, Khan H, Chang V, Batish M, Gavrilova T, Badiane F, Degheidy H, Marti G, Raveche E.

Oncogene. 2014 Jun 19;33(25):3307-15. doi: 10.1038/onc.2013.291. Epub 2013 Sep 2.

7.

MicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders.

Yuan Y, Kasar S, Underbayev C, Prakash S, Raveche E.

Leuk Res Treatment. 2012;2012:603830. doi: 10.1155/2012/603830. Epub 2012 Jun 17.

8.

MicroRNAs and induced pluripotent stem cells for human disease mouse modeling.

Underbayev C, Kasar S, Yuan Y, Raveche E.

J Biomed Biotechnol. 2012;2012:758169. doi: 10.1155/2012/758169. Epub 2012 Apr 30. Review.

9.

Role of microRNA-15a in autoantibody production in interferon-augmented murine model of lupus.

Yuan Y, Kasar S, Underbayev C, Vollenweider D, Salerno E, Kotenko SV, Raveche E.

Mol Immunol. 2012 Sep;52(2):61-70. doi: 10.1016/j.molimm.2012.04.007. Epub 2012 May 11.

10.

Systemic in vivo lentiviral delivery of miR-15a/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia.

Kasar S, Salerno E, Yuan Y, Underbayev C, Vollenweider D, Laurindo MF, Fernandes H, Bonci D, Addario A, Mazzella F, Raveche E.

Genes Immun. 2012 Feb;13(2):109-19. doi: 10.1038/gene.2011.58. Epub 2011 Sep 1.

11.

The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia.

Salerno E, Yuan Y, Scaglione BJ, Marti G, Jankovic A, Mazzella F, Laurindo MF, Despres D, Baskar S, Rader C, Raveche E.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S98-109. doi: 10.1002/cyto.b.20544.

12.

Prevalence of monoclonal B-cell lymphocytosis: a systematic review.

Shim YK, Middleton DC, Caporaso NE, Rachel JM, Landgren O, Abbasi F, Raveche ES, Rawstron AC, Orfao A, Marti GE, Vogt RF.

Cytometry B Clin Cytom. 2010;78 Suppl 1:S10-8. doi: 10.1002/cyto.b.20538. Review.

13.

Antitumor activity of type I and type III interferons in BNL hepatoma model.

Abushahba W, Balan M, Castaneda I, Yuan Y, Reuhl K, Raveche E, de la Torre A, Lasfar A, Kotenko SV.

Cancer Immunol Immunother. 2010 Jul;59(7):1059-71. doi: 10.1007/s00262-010-0831-3. Epub 2010 Mar 9.

14.

Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity.

Salerno E, Scaglione BJ, Coffman FD, Brown BD, Baccarini A, Fernandes H, Marti G, Raveche ES.

Mol Cancer Ther. 2009 Sep;8(9):2684-92. doi: 10.1158/1535-7163.MCT-09-0127. Epub 2009 Sep 1.

15.

Regulatory T cells as central regulators of both autoimmunity and B cell malignancy in New Zealand Black mice.

Scaglione BJ, Salerno E, Gala K, Pan M, Langer JA, Mostowski HS, Bauer S, Marti G, Li Y, Tsiagbe VK, Raveche ES.

J Autoimmun. 2009 Feb;32(1):14-23. doi: 10.1016/j.jaut.2008.10.001. Epub 2008 Nov 20.

PMID:
19022624
16.

Mutation of the IFNAR-1 receptor binding site of human IFN-alpha2 generates type I IFN competitive antagonists.

Pan M, Kalie E, Scaglione BJ, Raveche ES, Schreiber G, Langer JA.

Biochemistry. 2008 Nov 18;47(46):12018-27. doi: 10.1021/bi801588g. Epub 2008 Oct 21.

PMID:
18937499
17.

Overview of monoclonal B-cell lymphocytosis.

Marti G, Abbasi F, Raveche E, Rawstron AC, Ghia P, Aurran T, Caporaso N, Shim YK, Vogt RF.

Br J Haematol. 2007 Dec;139(5):701-8. Review.

PMID:
18021084
18.

Chronic lymphocytic leukaemia genetics overview.

Caporaso N, Goldin L, Plass C, Calin G, Marti G, Bauer S, Raveche E, McMaster ML, Ng D, Landgren O, Slager S.

Br J Haematol. 2007 Dec;139(5):630-4. Review.

PMID:
18021078
19.

Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model.

Scaglione BJ, Salerno E, Balan M, Coffman F, Landgraf P, Abbasi F, Kotenko S, Marti GE, Raveche ES.

Br J Haematol. 2007 Dec;139(5):645-57. Epub 2007 Oct 17. Review.

20.

B-cell repertoire and clonal analysis in unaffected first degree relatives in familial chronic lymphocytic leukaemia kindred.

Abbasi F, Longo NS, Lipsky PE, Raveche E, Schleinitz TA, Stetler-Stevenson M, Caporaso N, Marti G.

Br J Haematol. 2007 Dec;139(5):820-3. Epub 2007 Oct 17.

PMID:
17941936
21.

Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice.

Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC, Fredrickson T, Landgraf P, Ramachandra S, Huppi K, Toro JR, Zenger VE, Metcalf RA, Marti GE.

Blood. 2007 Jun 15;109(12):5079-86. Epub 2007 Mar 9.

22.

Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein.

Mansour A, Chang VT, Srinivas S, Harrison J, Raveche E.

Cancer Immunol Immunother. 2007 Apr;56(4):501-14. Epub 2006 Oct 19.

PMID:
17051411
23.

Characterization of the mouse IFN-lambda ligand-receptor system: IFN-lambdas exhibit antitumor activity against B16 melanoma.

Lasfar A, Lewis-Antes A, Smirnov SV, Anantha S, Abushahba W, Tian B, Reuhl K, Dickensheets H, Sheikh F, Donnelly RP, Raveche E, Kotenko SV.

Cancer Res. 2006 Apr 15;66(8):4468-77.

24.

Evidence of Borrelia autoimmunity-induced component of Lyme carditis and arthritis.

Raveche ES, Schutzer SE, Fernandes H, Bateman H, McCarthy BA, Nickell SP, Cunningham MW.

J Clin Microbiol. 2005 Feb;43(2):850-6.

25.

Genistein induces G2 arrest in malignant B cells by decreasing IL-10 secretion.

Mansour A, McCarthy B, Schwander SK, Chang V, Kotenko S, Donepudi S, Lee J, Raveche E.

Cell Cycle. 2004 Dec;3(12):1597-605. Epub 2004 Dec 8.

PMID:
15611648
26.

RNA interference of IL-10 in leukemic B-1 cells.

McCarthy BA, Mansour A, Lin YC, Kotenko S, Raveche E.

Cancer Immun. 2004 Jul 23;4:6.

27.

Studies in NZB IL-10 knockout mice of the requirement of IL-10 for progression of B-cell lymphoma.

Czarneski J, Lin YC, Chong S, McCarthy B, Fernandes H, Parker G, Mansour A, Huppi K, Marti GE, Raveche E.

Leukemia. 2004 Mar;18(3):597-606.

PMID:
14712288
28.

Investigation of promoter polymorphisms in the tumor necrosis factor-alpha and interleukin-10 genes in liver transplant patients.

Fernandes H, Koneru B, Fernandes N, Hameed M, Cohen MC, Raveche E, Cohen S.

Transplantation. 2002 Jun 27;73(12):1886-91.

PMID:
12131682
29.

Cell cycle effects of IL-10 on malignant B-1 cells.

Yen Chong S, Lin YC, Czarneski J, Zhang M, Coffman F, Kashanchi F, Raveche E.

Genes Immun. 2001 Aug;2(5):239-47.

30.

The growth-regulatory role of B-cell-specific activator protein in NZB malignant B-1 cells.

Chong SY, Zhang M, Lin YC, Coffman F, Garcia Z, Ponzio N, Raveche ES.

Cancer Immunol Immunother. 2001 Mar;50(1):41-50.

PMID:
11315509
31.

The role of B-cell-specific activator protein in the response of malignant B-1 cells to LPS.

Zhang M, Chong SY, Raveche ES.

Exp Cell Res. 2001 Apr 1;264(2):233-43.

PMID:
11262180
32.

Antisense IL-10 abrogates the inhibitory effects of IL-10 production by transfected tumor cells.

Parker G, Fernandes H, Chong SY, Czarneski J, Ra H, Lin YC, Raveche E.

Cytokines Cell Mol Ther. 2000 Sep;6(3):113-9.

PMID:
11140879
33.

A poly(C) repeat polymorphism in the promoter of the IL-10 gene in NZB mice.

Morse HR, Bidwell JL, Raveche ES.

Eur J Immunogenet. 1999 Oct;26(5):377-8. No abstract available.

PMID:
10553506
34.

In vivo and in vitro antiproliferative effects of antisense interleukin 10 oligonucleotides.

Parker GA, Peng B, He M, Gould-Fogerite S, Chou CC, Raveché ES.

Methods Enzymol. 2000;314:411-29. No abstract available.

PMID:
10565029
35.

Effects of cord blood transfer on the hematopoietic recovery following sublethal irradiation in MRL lpr/lpr mice.

Czarneski J, Lin YC, Ende N, Ponzio NM, Raveche E.

Proc Soc Exp Biol Med. 1999 Feb;220(2):79-87.

PMID:
9933501
36.

Regulatory role of T cells in a murine model of lymphoproliferative disease.

Raveche E, Fernandes H, Ong H, Peng B.

Cell Immunol. 1998 Jul 10;187(1):67-75.

PMID:
9682005
37.

The correlation of telomerase and IL-10 with leukemia transformation in a mouse model of chronic lymphocytic leukemia (CLL).

Peng B, Zhang M, Sun R, Lin YC, Chong SY, Lai H, Stein D, Raveche ES.

Leuk Res. 1998 Jun;22(6):509-16.

PMID:
9678717
38.
39.

Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis.

König A, Menzel T, Lynen S, Wrazel L, Rosén A, Al-Katib A, Raveche E, Gabrilove JL.

Leukemia. 1997 Feb;11(2):258-65.

PMID:
9009090
40.

Requirement for increased IL-10 in the development of B-1 lymphoproliferative disease in a murine model of CLL.

Ramachandra S, Metcalf RA, Fredrickson T, Marti GE, Raveche E.

J Clin Invest. 1996 Oct 15;98(8):1788-93.

41.

Altered CD45 expression in malignant B-1 cells.

Dang AM, Phillips JA, Lin T, Raveche ES.

Cell Immunol. 1996 May 1;169(2):196-207.

PMID:
8620547
42.

Altered calcium signal transduction in B-1 malignant cells.

Dang AM, Balasubramanyam M, Garcia Z, Raveche E, Gardner JP.

Immunol Cell Biol. 1995 Dec;73(6):511-20.

PMID:
8713472
43.

Regulation of cll by interleukin-10 - role of antisense IL-10.

Fernandes H, Barchuk W, Fernandes G, Ramachandra S, Chou C, Raveche E.

Oncol Rep. 1995 Nov;2(6):985-9.

PMID:
21597839
44.

Effect of human cord blood transfer on survival and disease activity in MRL-lpr/lpr mice.

Ende N, Czarneski J, Raveche E.

Clin Immunol Immunopathol. 1995 May;75(2):190-5.

PMID:
7704978
45.

Growth inhibition of malignant CD5+B (B-1) cells by antisense IL-10 oligonucleotide.

Peng B, Mehta NH, Fernandes H, Chou CC, Raveché E.

Leuk Res. 1995 Mar;19(3):159-67.

PMID:
7535370
46.

The natural history of a lymphoproliferative disorder in aged NZB mice.

Marti GE, Metcalf RA, Raveche E.

Curr Top Microbiol Immunol. 1995;194:117-26.

PMID:
7895486
47.

A cultured malignant B-1 line serves as a model for Richter's syndrome.

Peng B, Sherr DH, Mahboudi F, Hardin J, Wu YH, Sharer L, Raveché ES.

J Immunol. 1994 Aug 15;153(4):1869-80.

PMID:
8046247
48.

Apoptosis induction in CD5+(Ly1+) malignant B cells.

Peng B, Raveche E.

Leukemia. 1993 Jun;7(6):789-94.

PMID:
7684796
49.

IL-10 production in a CD5+ B cell lymphoma arising in a CD4 monoclonal antibody-treated SJL mouse.

Lin TZ, Fernandes H, Yauch R, Ponzio NM, Raveche E.

Clin Immunol Immunopathol. 1992 Oct;65(1):10-22.

PMID:
1382908
50.

Supplemental Content

Loading ...
Support Center